Latest Ratios: P/E Ratio -13.8x · EV/EBITDA N/A · ROE -62.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $477M | $289M | $387M | $191M | $760M | — | — |
| Enterprise Value | $1.8B | $463M | $258M | $330M | $154M | $527M | — | — |
| P/E Ratio → | -13.83 | — | — | — | — | — | — | — |
| P/S Ratio | 647.01 | 170.48 | 63.70 | 67.60 | 33.20 | 158.87 | — | — |
| P/B Ratio | 8.39 | 2.52 | 1.61 | 2.19 | 0.70 | 2.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 165.22 | 56.84 | 57.72 | 26.76 | 110.24 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -319.4% | -319.4% | -1277.6% | -731.9% | -925.0% | -832.4% | -139.5% | 100.0% |
| Operating Margin | -4454.2% | -4454.2% | -2401.6% | -2020.2% | -1857.5% | -1573.4% | -278.3% | -304.1% |
| Net Profit Margin | -4113.7% | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | -300.3% | -319.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -62.5% | -62.5% | -58.0% | -49.1% | -32.8% | -46.6% | -111.1% | — |
| ROA | -53.6% | -53.6% | -47.9% | -41.1% | -28.1% | -39.2% | -26.6% | -33.8% |
| ROIC | -58.0% | -58.0% | -61.0% | -48.5% | -43.2% | -77.7% | — | — |
| ROCE | -65.9% | -65.9% | -58.4% | -48.3% | -31.3% | -32.0% | -28.2% | -39.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.06 | 0.09 | 0.08 | 0.05 | 0.22 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.17 | -0.32 | -0.13 | -0.64 | -0.83 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -596.74 | -596.74 | -190.24 | -92.75 | -109.83 | -21.66 | -21.64 | -23.57 |
Net cash position: cash ($20M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.57 | 6.57 | 4.67 | 4.08 | 6.17 | 8.07 | 7.25 | 3.94 |
| Quick Ratio | 6.57 | 6.57 | 4.67 | 4.08 | 5.68 | 7.75 | 7.25 | 3.94 |
| Cash Ratio | 6.34 | 6.34 | 3.92 | 3.30 | 5.43 | 7.46 | 6.92 | 3.78 |
| Asset Turnover | — | 0.01 | 0.02 | 0.03 | 0.02 | 0.01 | 0.05 | 0.11 |
| Inventory Turnover | — | — | — | — | 3.92 | 4.24 | — | — |
| Days Sales Outstanding | — | — | — | 139.73 | 98.44 | 108.77 | 121.72 | 39.34 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $137M | $110M | $92M | $91M | $93M | $92M | $92M |
Imminent liquidity exhaustion
Based on current market data, Absci trades at a P/S ratio of 606.36, a figure that appears untethered from fundamental performance and suggests investors are pricing the firm as a high-upside call option on AI-driven drug discovery rather than a traditional service-based biotechnology entity.
The extreme valuation multiple implies that the market is heavily discounting the current revenue contraction in favor of potential future milestone-driven windfalls. This pricing structure warrants caution, as it leaves the equity highly sensitive to any delays in clinical validation or further dilution required to bridge the current funding gap.
As reported in recent financial statements, Absci’s ROIC has remained consistently negative, hovering near -13.5% in 2026Q1, which indicates that the company is currently destroying shareholder value through its high-burn research model rather than compounding returns on its invested capital base.
The inability to generate positive returns on capital is a direct consequence of the massive R&D expenditure required to maintain the proprietary 'SoluPro' platform. Without a transition to high-margin royalty streams, the current trajectory suggests that capital efficiency will remain elusive, further pressuring the firm's long-term viability.
According to quarterly filings, Absci’s Days Sales Outstanding (DSO) has exhibited extreme volatility, reaching 207 days in 2025Q3, which highlights the inherent difficulty in predicting cash inflows from milestone-based pharmaceutical collaborations compared to more stable, recurring revenue business models.
This erratic working capital cycle suggests that the company lacks leverage in its customer relationships, often waiting extended periods for milestone payments to materialize. Investors should monitor whether this inefficiency persists, as it directly exacerbates the firm's already precarious liquidity position.
Based on the reported 2026Q1 figures, the company’s current ratio of 6.59 appears superficially strong, yet this metric masks a rapidly depleting cash balance that is insufficient to cover the ongoing quarterly operating losses of over $30 million.
While the current ratio suggests an ability to meet short-term obligations, the underlying cash burn rate indicates that the company is approaching a critical liquidity threshold. The reliance on external financing to sustain operations remains the primary risk to the firm's ability to continue as a going concern.
The P/S ratio is the most commonly misapplied metric for Absci, as it fails to account for the non-recurring, milestone-heavy nature of the company's revenue, which obscures the underlying unit economics of its AI-driven drug discovery platform.
Analysts should instead focus on 'burn-per-program' or 'active program count' to better assess the platform's commercial traction. Relying on P/S in a pre-revenue, high-burn environment risks misinterpreting a temporary milestone payment as a sign of sustainable, scalable growth.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABSI stock.
Absci Corporation's current P/E ratio is -13.8x. This places it at the 50th percentile of its historical range.
Absci Corporation's return on equity (ROE) is -62.5%. The historical average is -60.0%.
Based on historical data, Absci Corporation is trading at a P/E of -13.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Absci Corporation has -319.4% gross margin and -4454.2% operating margin.